Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice

This on-demand programme, Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice, has been developed to further education among practicing cardiologists to ensure understanding of the latest ARNI data in HFpEF and HFrEF, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of ARNI therapy in appropriate heart failure patients.

The programme brings together a leading international faculty from Malaysian, US, Germany, Singapore, for a four-part series, featuring eight videos.

This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.

Learning Objectives

  1. Understand the latest ARNI data in HFpEF and HFrEF   
  2. Understand how emerging data relates to current practice in Malaysia  
  3. Apply current understanding of ARNI therapy in appropriate heart failure patients 
     

DISCLOSURES

In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.

This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.
 

R-CME DISCLAIMER / TERMS & CONDITIONS

Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA)  for 1 hour of external CPD credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity.
 

INSTRUCTIONS TO PARTICIPANTS

There is no fee for taking part in this online learning activity.

Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Course summary
Available credit: 
  • 1.00 Malaysian Medical Association (MMA)
Course opens: 
03/23/2021
Course expires: 
03/15/2022
Cost:
£0.00
Rating: 
5

PART 1: Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF

  • Prof Carolyn Lam, Professor of Cardiology, National Heart Centre Singapore Duke-NUS, Singapore
  • Prof Wan Azman Wan Ahmad, Professor and Senior Consultant of Cardiologist at University of Malaya Medical Centre, Kuala Lumpur, Malaysia

PART 2: Meet the Expert Q&A – Local Interpretation of Emerging ARNI Data in HF

  • Prof Carolyn Lam, Professor of Cardiology, National Heart Centre Singapore Duke-NUS, Singapore
  • Prof Wan Azman Wan Ahmad, Professor and Senior Consultant of Cardiologist at University of Malaya Medical Centre, Kuala Lumpur, Malaysia

PART 3: Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs)

  • Prof Carolyn Lam, Professor of Cardiology, National Heart Centre Singapore Duke-NUS, Singapore

PART 4a: Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF

  • Dr Azmee Modh Ghazi, Cardiologist, National Heart Institute, Kuala Lumpur, Malaysia

PART 4b: Clinical questions on ARNI therapy – Chapter 2: ARNI Therapy Mode of Action

  • Dr James L Januzzi, Director of the Cardiac Intensive Care Unit, Massachusetts General Hospital, US
  • Dr Akshay S Desai, Brigham and Women’s Hospital, Boston, MA, US
  • Dr Azmee Modh Ghazi, Cardiologist, National Heart Institute, Kuala Lumpur, Malaysia

PART 4c: Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure

  • Dr Azmee Modh Ghazi, National Heart Institute, Kuala Lumpur, Malaysia
  • Dr David Morrow, Cardiovascular Division, Brigham and Women’s Hospital, US

PART 4d: Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure

  • Dr Azmee Modh Ghazi, Cardiologist , National Heart Institute, Kuala Lumpur, Malaysia
  • Rolf Wachter, Associate Professor, University of Leipzig, Leipzig, Germany

PART 4e: Clinical questions on ARNI therapy – Chapter 5: Summary

  • Dr Azmee Modh Ghazi, Cardiologist , National Heart Institute, Kuala Lumpur, Malaysia

This programme was developed for online administration only.

Faculty Biographies

Wan Azman Wan Ahmad, Professor and Senior Consultant of Cardiologist at University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Prof Wan Azman Wan Ahmad is Professor and Senior Consultant of Cardiologist at University of Malaya Medical Centre, Kuala Lumpur, Malaysia. He graduated from University of Malaya in 1983 and currently serves as President of the National Heart Association of Malaysia.

Carolyn Lam, Professor and Senior Consultant, National Heart Centre Singapore Duke-NUS, Singapore

Prof Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Prof Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials.

Azmee Modh Ghazi, National Heart Institute, Kuala Lumpur, MY

Dr Azmee Mohd Ghazi is a Cardiologist at the National Heart Centre, Malaysia, where he serves as Clinical Director for Heart Failure and Heart Transplant. Specialising in coronary intervention, cardiac transplantation, advanced adult heart failure and pulmonary hypertension, Dr Azmee undertakes a number of procedures including coronary intervention (PCI), right heart catheterisation, and echocardiography.

James L Januzzi, Director of the Cardiac Intensive Care Unit, Massachusetts General Hospital, US

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has in-depth experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing. He speaks widely on the topic of biomarker testing in heart disease and treatment of heart failure.

Akshay S Desai, Brigham and Women’s Hospital, Boston, MA, US

Prof Akshay Desai is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions.  Prof Desai received his medical degree from HMS. He completed an internal medicine residency as well as fellowships in cardiovascular medicine, vascular medicine and advanced heart disease at BWH. He is board certified in and cardiovascular disease, as well as advanced heart failure and transplant cardiology.

David Morrow, Cardiovascular Division, Brigham and Women’s Hospital

Prof David A Morrow the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women's Hospital and a Professor of Medicine at Harvard Medical School. He directs the TIMI Biomarker Program.

Rolf Wachter, Associate Professor, University of Leipzig, Leipzig, Germany

Prof Rolf Wachter is Director of Cardiology at the Clinic and Policlinic for Cardiology, University Hospital Leipzig. Prior to this, he served as Deputy Director (Leitender Oberarzt), Clinic for Cardiology and Pneumology, University Medicine Göttingen, Germany.

 

This programme is supported by an unrestricted educational grant from Novartis.

Available Credit

  • 1.00 Malaysian Medical Association (MMA)

Price

Cost:
£0.00
Please login or register to take this course.